TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsIndonesia’s first blood plasma facility to begin operations next year
The Karawang facility is being developed by PT SK Plasma Core Indonesia, a joint venture between South Korea's SK Plasma and Indonesia's sovereign wealth fund INA, with an investment of US$150 million.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Potential therapy: People who recovered from COVID-19 donate convalescent plasma on Tuesday at the Indonesian Red Cross Jakarta’s blood donation center on Jl. Kramat Raya in Central Jakarta. The government on Monday launched the National Convalescent Plasma Drive to increase the recovery rate and reduce the fatality rate of COVID-19 patients. (JP/Seto Wardhana)
H
ealth Minister Budi Gunadi Sadikin stated that the blood plasma processing facility in Karawang, West Java, which aims to reduce reliance on imported high-value biological medicines, could begin operations early next year.
"We [still] import these products, even though Indonesia has one of the world's largest blood resources due to its large population," Budi said on Wednesday in Jakarta, as quoted by Bisnis.
The plant is expected to produce up to 600,000 liters of plasma-derived products annually once fully operational, with pending regulatory approvals from the Food and Drug Monitoring Agency (BPOM).
Budi said the government was pushing for a swift approval process, so production could start according to the schedule.
"I'm asking BPOM not to take too long with the approval process. The company is ready to start production and the factory has already been completed," Budi said.
The Karawang facility is being developed by PT SK Plasma Core Indonesia, a joint venture between South Korea's SK Plasma and Indonesia's sovereign wealth fund INA, with an investment of US$150 million.
Once operational, the facility will manufacture plasma-derived therapies such as albumin, intravenous immunoglobulin (IVIG) and blood clotting factors, products whose domestic demand continues to grow alongside Indonesia's healthcare needs.
